Palonosetron intravenous - Exela Pharma Sciences

Drug Profile

Palonosetron intravenous - Exela Pharma Sciences

Alternative Names: Palonosetron hydrochloride intravenous - Exela Pharma Sciences

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exela Pharma Sciences
  • Class Antiemetics; Isoquinolines; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 31 Aug 2016 Chemical structure information added
  • 22 Aug 2016 Registered for Chemotherapy induced nausea and vomiting (Prevention) in USA (IV)
  • 22 Mar 2016 FDA issues tentative approval to palonosetron (0.125 mg/ml) injection for the prevention of Chemotherapy induced nausea and vomiting (In adults) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top